Boston Scientific Announces Results For Second Quarter 2016

Go back to Boston Scientific Announces Results For Second Quarter 2016

Wedbush Raises Price Target on Boston Scientific (BSX) to $25 Following 2Q

July 29, 2016 8:14 AM EDT

Wedbush reiterated a Neutral rating on Boston Scientific (NYSE: BSX), and raised the price target to $25.00 (from $23.00), following the company's 2Q earnings report. Total sales were $2.126 billion, and $80 million ahead of consensus, while adjusted EPS of $0.27 was in line.

Analyst Tao Levy... More

Boston Scientific (BSX) PT Raised to $28 at Needham & Company

July 28, 2016 2:38 PM EDT

Needham & Company analyst Mike Matson reiterated a Buy rating and bumped his price target on Boston Scientific (NYSE: BSX) to $28.00 (from $26.00) following doubled-digit organic growth in Q2.

Matson commented, "BSX beat consensus 2Q16 revenue and met consensus EPS. BSX's organic constant currency... More

Boston Scientific (BSX) PT Bumped to $26 at Evercore ISI

July 28, 2016 12:46 PM EDT

Evercore ISI analyst Vijay Kumar reiterated a Buy rating and lifted his price target on Boston Scientific (NYSE: BSX) to $26.00 (from $25.50) following results this morning.

The firm maintained FY 2016 EPS of $1.11, FY 2017 EPS of $1.30 and raised FY 2018 EPS from $1.52 to $1.55.

Kumar commented, "Just when investors sighed a breath of relief after last Q when the long awaited new product momentum drove a... More

Boston Scientific (BSX) Reports In-Line Q2 EPS; Bumps FY16 Rev View

July 28, 2016 6:34 AM EDT

Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.27, in-line with the analyst estimate of $0.27. Revenue for the quarter came in at $2.13 billion versus the consensus estimate of $2.05 billion.

"Our strong performance is evidence of the success of our category leadership strategy," said Mike... More